Caredx, Inc. (CDNA): Neil Gagnon , 10% owner of Caredx, Inc. purchased 93,240 shares on Apr 14, 2016. The Insider buying transaction was reported by the company on Apr 18, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.03 per share for a total value of $374,744.16 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Oct 23, 2015, Neil Gagnon (10% owner) purchased 1,431 shares at $4.99 per share price.On Jun 3, 2015, Peter Maag (CEO) purchased 2,000 shares at $4.84 per share price.
Shares of CareDx Inc (CDNA) ended Monday, Apr 18, 2016 session in red amid volatile trading. The shares closed down -0.1 points or -2.25% at $4.35 with 31,755 shares getting traded. Post opening the session at $4.57, the shares hit an intraday low of $4.3 and an intraday high of $4.57 and the price vacillated in this range throughout the day. The company has a market cap of $52 M and the number of outstanding shares has been calculated to be 1,19,66,899 shares. The 52-week high of CareDx Inc is $8 and the 52-week low is $3.7.
Currently the company Insiders own 12.85% of CareDx Inc shares according to the proxy statements.Institutional Investors own 41.04% of CareDx Inc shares.During last six month period, the net percent change held by insiders has seen a change of 0.18%.
CareDx Inc. formerly XDx Inc. is a commercial-stage company which develops markets and delivers a diagnostic surveillance solution for heart transplant recipients. The Company’s commercialized testing solution the AlloMap heart transplant molecular test or AlloMap is a non-invasive blood-based test used to monitor heart transplant recipients for acute cellular rejection. AlloMap uses gene expression technology for the identification of heart transplant recipients. AlloMap provides a single integer score ranging from 0 to 40 and determines the probability of moderate to severe acute cellular rejection. As of December 31 2014 the Company performed more than 66000 commercial AlloMap tests in total. The Company is also engaged in the new product development in other areas of transplant surveillance such as the use of cell-free donor de-oxy ribonucleic acid (cfDNA) technology as a biomarker for rejection.